STOCK TITAN

Integra Lifesciences Hldgs Cp - IART STOCK NEWS

Welcome to our dedicated page for Integra Lifesciences Hldgs Cp news (Ticker: IART), a resource for investors and traders seeking the latest updates and insights on Integra Lifesciences Hldgs Cp stock.

Overview

Integra Lifesciences Holdings Corp (IART) is a New Jersey-based medical technology company that designs and manufactures a broad spectrum of advanced medical devices and surgical instruments. Serving global markets, Integra focuses on regenerative therapies, orthopedic extremity surgery, and neurosurgical applications. The firm operates through its two primary segments: Codman Specialty Surgical and Tissue Technologies, each addressing specific surgical needs with precision and innovative solutions.

Core Business Areas

Integra is dedicated to reducing uncertainty in the operating room by providing reliable, high-quality products for use in:

  • Orthopedic Extremity Surgery: Devices and implants engineered for improved outcomes in spine, foot and ankle, hand and wrist, shoulder and elbow procedures, as well as tendon and peripheral nerve protection and repair.
  • Neurosurgery: A comprehensive portfolio of implants, devices, instruments, and systems used in neurosurgery, neurotrauma management, continuous intracranial pressure monitoring, and neuromonitoring, leveraging advanced data presentation and MR conditional technology.
  • Regenerative and Tissue Technologies: Innovative solutions for reconstructive and general surgeries, focusing on tissue repair and regeneration that enhance patient recovery and surgical precision.

Market Position and Significance

Integra stands as a significant player in the medical device industry through its commitment to innovation and high-quality manufacturing standards. Its diversified product portfolio not only addresses a wide range of surgical challenges but also enhances patient care by enabling surgeons to focus better on treatment outcomes. The company’s practices, which include strategic acquisitions and investments in state-of-the-art manufacturing facilities, position it within a highly competitive landscape where operational excellence and product reliability are paramount.

Operational Excellence and Supply Chain

With a focus on streamlining manufacturing processes and ensuring the highest quality systems, Integra continuously refines its operational model. Its integrated supply chain and adherence to rigorous quality standards enable it to manage regulatory requirements while efficiently delivering innovative surgical solutions. The emphasis on quality, reliability, and a diversified manufacturing base is key to supporting robust market demand and maintaining consistent product availability across domestic and international markets.

Innovation and Expertise

Driven by the goal of restoring patients' lives, Integra leverages its deep industry expertise to innovate treatment pathways across surgical, neurologic, and regenerative care. Its commitment to research, development, and the integration of technological advancements ensures that surgeons and healthcare professionals have access to cutting-edge tools and instruments designed to meet the evolving demands of modern medicine.

Competitive Landscape

In a competitive market that features several major medical technology firms, Integra distinguishes itself through its targeted product development and clear focus on improving clinical outcomes. It addresses the challenges of integrating new technologies with traditional surgical practices, emphasizing innovation while maintaining rigorous quality control and operational consistency.

Investor and Analyst Insights

For investors and market analysts, Integra offers a detailed narrative of operational resilience and strategic execution. The company’s clear segmentation into specialty surgical and tissue technologies provides transparency into its revenue streams and market focus. Its global presence, combined with a commitment to operational excellence, ensures that its products remain at the forefront of surgical innovation and patient care.

Rhea-AI Summary
Integra LifeSciences launches MicroMatrix Flex, a dual-syringe system for precise delivery of UBM technology, expanding wound reconstruction capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
none
-
Rhea-AI Summary
Integra LifeSciences Holdings Corporation announces CEO Jan De Witte's retirement by the end of 2024. Stuart Essig appointed as executive chairman of the Board. A search for a new CEO is underway.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.65%
Tags
management
-
Rhea-AI Summary
Integra LifeSciences (IART) reported Q4 2023 revenues of $397.0 million, a 0.2% decrease from the previous year. Full-year 2023 revenues were $1,541.6 million, a 1.0% decrease. Adjusted earnings per diluted share for Q4 were $0.89, down from $0.94 in 2022. For the full year, adjusted earnings were $3.10, compared to $3.36 in 2022. The company highlighted successful business achievements and strategic acquisitions, along with revenue growth in specific segments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.65%
Tags
Rhea-AI Summary
Integra LifeSciences Holdings Corporation (IART) is set to release its fourth quarter and full year 2023 financial results on February 28, 2024. The management team will host a conference call at 8:30 a.m. ET, with a live webcast available on the Investors section of the company's website. Participants can register for the call and access dial-in details. A webcast replay will also be available on the Investors section of the website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
conferences earnings
-
Rhea-AI Summary
Integra LifeSciences Holdings Corporation (NASDAQ: IART) CEO to Present at J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags
conferences
-
Rhea-AI Summary
Integra LifeSciences Holdings Corporation (Nasdaq: IART) has announced the acquisition of Acclarent, Inc. from Ethicon, Inc., a Johnson & Johnson MedTech company, for $275 million in cash at closing, subject to customary purchase price adjustments, and an additional $5 million upon the achievement of certain regulatory milestones. The acquisition will become part of Integra’s Codman Specialty Surgical (CSS) division, making Integra one of the leading providers of ENT products and technologies. The U.S. ENT specialty devices market is growing at 5-6% and will add approximately $1 billion to the CSS global total addressable market. The Acclarent portfolio includes groundbreaking balloon technologies for sinus dilation and eustachian tube dilation as well as surgical navigation systems.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.03%
Tags
Rhea-AI Summary
Integra LifeSciences Holdings Corporation (Nasdaq: IART) appoints Jeff Graves, Ph.D., president and CEO of 3D Systems Corporation, to its board of directors. Dr. Graves brings a wealth of experience from leading and transforming technically complex businesses, including his roles at 3D Systems, MTS Systems Corporation, and C&D Technologies, Inc. His expertise in streamlining global operations and delivering differentiated solutions will be valuable to Integra's board and shareholders. With the addition of Dr. Graves, Integra has welcomed four new directors since 2021, signaling a commitment to enhancing the board's expertise and diversity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
management
-
Rhea-AI Summary
Integra LifeSciences reports Q3 2023 financial results with a decline in revenues and earnings per share compared to the prior year. The company remains on track to restart the Boston manufacturing facility and has achieved milestones with the relaunch of CereLink in international markets and submission for regulatory approval in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.97%
Tags
-
Rhea-AI Summary
Integra LifeSciences Holdings Corporation will release Q3 2023 financial results on October 25, 2023. Conference call at 8:30 a.m. ET. Webcast replay available on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
conferences earnings
Rhea-AI Summary
Perimeter Medical Imaging AI, Inc. appoints Adam Hodges as VP of Sales and Marketing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
management AI

FAQ

What is the current stock price of Integra Lifesciences Hldgs Cp (IART)?

The current stock price of Integra Lifesciences Hldgs Cp (IART) is $19.57 as of April 4, 2025.

What is the market cap of Integra Lifesciences Hldgs Cp (IART)?

The market cap of Integra Lifesciences Hldgs Cp (IART) is approximately 1.5B.

What are the primary business segments of Integra Lifesciences?

Integra operates primarily through its Codman Specialty Surgical and Tissue Technologies segments, focusing on advanced medical devices for surgical applications.

How does Integra support surgical procedures?

By offering innovative devices and implants for orthopedic, neurosurgical, and regenerative procedures, Integra helps reduce uncertainty in the operating room and improves patient outcomes.

What types of products does Integra develop?

Integra develops a wide range of medical devices including surgical instruments, implants, and monitoring systems designed for orthopedic extremity surgeries, neurosurgery, and tissue repair.

Which markets does Integra serve?

Integra serves a diverse range of markets, including domestic sales in the United States and international markets across Europe, Asia Pacific, and other regions.

How does Integra differentiate itself in a competitive landscape?

The company differentiates itself through a robust portfolio of innovative products, strategic operational execution, and high-quality manufacturing practices, ensuring reliability and precision.

What role does innovation play at Integra?

Innovation is central to Integra's mission; the company continually advances surgical techniques and treatment pathways through research, development, and the integration of the latest technology.

How is Integra’s supply chain managed?

Integra maintains a rigorous supply chain with strategic investments in state-of-the-art manufacturing facilities, ensuring that product quality and regulatory compliance are consistently met.

What common investor concerns are addressed by Integra?

Investors typically seek clarity on the company’s operational efficiency, regulatory compliance, product innovation, and market positioning, all of which Integra addresses through transparent business segmentation and strategic investments.
Integra Lifesciences Hldgs Cp

Nasdaq:IART

IART Rankings

IART Stock Data

1.46B
66.16M
14.24%
91.53%
5.06%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
PRINCETON